Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.52 |
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | NOS2 | P35228 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317221 | 1.00 | UHRF1 (0.52) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL29505702 | 0.98 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL18765302 | 0.98 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL5010733 | 0.98 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E | |
| Formaldehyde SCHEMBL28853991 | 0.94 | UHRF1 (0.47) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL11616480 | 0.82 | UHRF1 (0.46) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL2750563 | 0.80 | UHRF1 (0.45) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL554353 | 0.80 | NOS3 (0.70) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL19413769 | 0.80 | UHRF1 (0.45) | UHRF1NOS3NOS1NOS2SLC6A4 | |
| SCHEMBL28198255 | 0.80 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136863-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120025328-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025327-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250066353-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| CN-114929694-B | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-112204006-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116813621-A | 9H purine compounds, pharmaceutical composition and application thereof | 江南大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-114621191-B | EZH2 inhibitor and preparation and application thereof | 东南大学 | 2023-08-15 | — | — | CN | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-114929694-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-4021905-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | Bayer Aktiengesellschaft (DE) | 2022-07-06 | — | — | EP | disclosed |
| CN-114621191-A | EZH2 inhibitor and preparation and application thereof | 东南大学 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066353-A1 | VANIN-1 INHIBITORS | VCAM1, TMBIM6, VNN1 | UHRF1 1319/4885NOS3 2266/4885NOS1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.